Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 405 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 20 minutes agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Doxorubicin | Phase 3 | Phase 3 | 0 | 0 | 4 | 20 | 0 | — | — | 1995-03 |
| Everolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 14 | 0 | — | — | 2004-03 |
| Lenalidomide | Phase 3 | Phase 3 | 0 | 0 | 1 | 10 | 0 | — | — | 2005-04 |
| Thalidomide | Phase 3 | Phase 3 | 0 | 0 | 1 | 8 | 0 | — | — | 1999-12 |
| Gemcitabine | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2000-03 |
| Cyproterone Acetate | Phase 3 | Phase 3 | 0 | 0 | 5 | 6 | 0 | — | — | 1987-05 |
| Sirolimus | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2006-08 |
| Vinblastine | Phase 3 | Phase 3 | 0 | 0 | 3 | 4 | 0 | — | — | 1996-08 |
| Galeterone | Phase 3 | Phase 3 | 0 | 0 | 1 | 3 | 0 | — | — | 2009-10 |
| Toremifene | Phase 3 | Phase 3 | 0 | 0 | 1 | 2 | 0 | — | — | 2001-04 |
| Diethylstilbestrol | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2002-12 |
| Ibandronic Acid | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2003-04 |
| Pembrolizumab | Phase 2 | Phase 2 | 18 | 6 | 0 | 45 | 0 | — | — | Nov 15, 2013 |
| Cyclophosphamide | Phase 2 | Phase 2 | 9 | 4 | 0 | 25 | 0 | — | — | 1999-10 |
| Fludarabine | Phase 2 | Phase 2 | 6 | 3 | 0 | 10 | 0 | — | — | Mar 8, 2017 |
| Fulvestrant | Phase 2 | Phase 2 | 3 | 2 | 0 | 10 | 0 | — | — | 2004-06 |
| Cemiplimab | Phase 2 | Phase 2 | 3 | 2 | 0 | 5 | 0 | — | — | Aug 12, 2019 |
| Trametinib | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Sep 23, 2014 |
| Tislelizumab | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Apr 12, 2021 |
| Sunitinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 14 | 0 | — | — | 2006-03 |
| Dasatinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 13 | 0 | — | — | 2007-01 |
| Avelumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 7 | 0 | — | — | Aug 2, 2017 |
| Palbociclib | Phase 2 | Phase 2 | 2 | 0 | 0 | 6 | 0 | — | — | 2014-06 |
| Copanlisib | Phase 2 | Phase 2 | 2 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Tazemetostat | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Nov 18, 2019 |
| Adavosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Verteporfin | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Mar 21, 2017 |
| Durvalumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 9 | 0 | — | — | Dec 15, 2016 |
| Bortezomib | Phase 2 | Phase 2 | 1 | 0 | 0 | 8 | 0 | — | — | Mar 20, 2003 |
| Capecitabine | Phase 2 | Phase 2 | 1 | 1 | 0 | 8 | 0 | — | — | 2000-03 |
| Vorinostat | Phase 2 | Phase 2 | 1 | 1 | 0 | 7 | 0 | — | — | 2000-01 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2008-08 |
| Cediranib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2004-03 |
| Pegfilgrastim | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2007-05 |
| Pertuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2003-04 |
| Trastuzumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 1998-10 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Jul 9, 2010 |
| Letrozole | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | Jan 30, 2023 |
| Ruxolitinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2008-02 |
| Afatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Fluorouracil | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2003-02 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2010-04 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Mar 17, 2011 |
| Crizotinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2014-08 |
| Dabrafenib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Disitamab Vedotin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 8, 2024 |
| Lenvatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 17, 2016 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.